Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo+ ADT Clear all

Conditions: Risk of Bone Fracture Occurrences
Interventions: Toremifene; Drug
Lead sponsor: GTx; Industry
Eligibility: 50 Years to 80 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Carcinoma
Interventions: Oxybutynin Chloride, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 103
States / cities: Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 77 more

Conditions: Prostatic Neoplasms
Interventions: Apalutamide, Androgen Deprivation Therapy (ADT), Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 2,517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 44
States / cities: La Jolla, California • Los Angeles, California • Orange, California + 36 more

Conditions: Prostate Cancer, Insulin Resistance
Interventions: Pioglitazone 30 mg, placebo tablet; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 85 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: Brexpiprazole, Seroquel XR, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more

Conditions: Prostate Cancer
Interventions: Aglatimagene besadenovec + valacyclovir, Placebo + valacyclovir; Biological
Lead sponsor: Candel Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2030
U.S. locations: 72
States / cities: Gilbert, Arizona • Glendale, Arizona • Peoria, Arizona + 56 more

Conditions: Major Depressive Disorder
Interventions: Placebo, Brexpiprazole, ADT; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more

Conditions: Prostate Cancer
Interventions: Placebo, Methylphenidate, Counseling Sessions, Sham Exercise, Standardized Exercise Intervention Program, Cognitive Behavioral Therapy (CBT); Other · Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy; Drug · Other · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more

Conditions: Depressive Disorder, Major
Interventions: SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 51
States / cities: Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 42 more

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Enzalutamide, Rucaparib camsylate, Placebo, Leuprolide Acetate, Goserelin Acetate, Degarelix, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 414
States / cities: Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 298 more

Conditions: Major Depressive Disorder
Interventions: SEP-363856, Placebo; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 929 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 53
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more

Conditions: Prostate Cancer, Osteoporosis, Fractures
Interventions: Toremifene Citrate; Drug
Lead sponsor: GTx; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 136
States / cities: Homewood, Alabama • Mobile, Alabama • Little Rock, Arkansas + 117 more

Conditions: Major Depressive Disorder (MDD)
Interventions: MSI-195, Placebo; Drug
Lead sponsor: MSI Methylation Sciences, Inc.; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 35
States / cities: Birmingham, Alabama • Encino, California • Escondido, California + 30 more

Conditions: Major Depressive Disorder
Interventions: Aripiprazole+ ADT, Placebo+ ADT; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 34
States / cities: Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 29 more

Conditions: Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
Interventions: Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 40 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Prostate Cancer
Interventions: Genistein, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Major Depressive Disorder
Interventions: Placebo, Brexpiprazole 1 mg, Brexpiprazole 3 mg; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 65 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: National City, California • Orlando, Florida

Conditions: Generalized Anxiety Disorder (GAD)
Interventions: ABBV-932, Placebo for ABBV-932, Antidepressant Therapy (ADT); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 49
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 43 more

Conditions: Social Anxiety Disorder
Interventions: Attention Disengagement Training (ADT), Placebo Condition; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: OPC-34712 + ADT, Placebo + ADT; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 826 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 37
States / cities: Arcadia, California • Beverly Hills, California • Fresno, California + 34 more

Conditions: Prostate Cancer
Interventions: N-111, Placebo; Dietary Supplement · Other
Lead sponsor: Optimal Health Research; Other
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, Fluciclovine F18, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography, PSMA PET Scan, Relugolix, Stereotactic Body Radiation Therapy; Procedure · Other · Drug + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2034
U.S. locations: 242
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 192 more

Conditions: Hot Flashes
Interventions: Active cooling device with cooling plate, Placebo device without cooling plate, Hot Flash Diary; Device · Other
Lead sponsor: Boston University; Other
Eligibility: 21 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer

Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Insulin Resistance and Androgen Deprivation Therapy

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy

Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)

A Study of Aripiprazole in Patients With Major Depressive Disorder

Autonomic and Renal Contributions to Hypertension With ADT

Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer

Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Attention Disengagement Training for Social Phobia

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)

Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Wrist Cooling for Hot Flashes Clinical Trial